Compare Regeneron Pharmaceuticals Inc (REGN) vs The Travelers Companies Inc. Common Stock (TRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs The Travelers Companies Inc. Common Stock — how do they compare? Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B), while The Travelers Companies Inc. Common Stock trades at $368.56 (market cap $77.23B). The key difference: Regeneron Pharmaceuticals Inc and The Travelers Companies Inc. Common Stock are close in size by market cap, and The Travelers Companies Inc. Common Stock pays the higher dividend (1.35%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and The Travelers Companies Inc. Common Stock for 1 Days on average.
| REGN | TRV | |
|---|---|---|
Market Cap | $76.14B | $77.23B |
Volume | 500,239 | 1,078,682 |
Sector | Health | Financials |
52-Week High | $852.03 | $397.22 |
52-Week Low | $557.73 | $261.57 |
Typical Hold Time | 107 Days | 1 Days |
Enterprise Value | $70.85B | $85.82B |
Dividend Yield | 0.51% | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About The Travelers Companies Inc. Common Stock
The Travelers Companies provides property and casualty insurance for individuals, businesses, and organizations. Its products include auto, home, and commercial coverage.
Read more on TRV →
